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Abstract
Objective—To evaluate longitudinal neuropsychological testing performance over a 12 month
period among HIV+ individuals, and to evaluate the impact of antiretroviral therapy (ART)
initiation on neuropsychological test changes in Uganda.
Methods—The study examined 77 HIV+ individuals recruited from the Infectious Diseases
Clinic at Makerere University, Uganda. They underwent detailed sociodemographic, medical
history, immune status, functional, neurologic, and neuropsychological evaluations at baseline and
12 months later. Thirty-one individuals initiated ART (ART group) after their baseline visit,
whereas 46 individuals were not placed on ART (no-ART group) during those 12 months. Paired
samples t-tests were used to evaluate longitudinal changes in neuropsychological test performance
for the entire sample, as well as for groups defined by ART initiation and baseline neurocognitive
status.
Results—The study evaluated 77 HIV individuals (62% women, mean age=37 years, mean
education=8 years, mean CD4 count=235 cells/μL). Both the ART and no-ART groups showed
significant improvements in tests of verbal memory, executive functioning, motor, and
psychomotor speed performance, as well as depression symptoms. The ART group had significant
improvements in CD4 count over the 12 months (p<.001) whereas the no-ART group had no CD4
count improvement.
Conclusion—ART use is associated with improvements in cognitive functioning among HIV+
individuals in Uganda. However, these improvements did not appear to be higher than those seen
among HIV+ individuals who did not initiate ART. Possible reasons for this include practice
effects among the no-ART group as well as improvements in their mood and overall quality of
life.
Address Correspondence to Dr. Ned Sacktor, Department of Neurology, Johns Hopkins Bayview Medical Center, 301 Building, Suite
2100, 4940 Eastern Ave. Baltimore, MD 21224, Tel: 410-550-1045, Fax: 410-550-0539, sacktor@jhmi.edu.
The authors declare that they have no conflict of interest.
NIH Public Access
Author Manuscript
J Neurovirol. Author manuscript; available in PMC 2014 February 01.
Published in final edited form as:














HIV; dementia; neurocognitive; neuropsychological assessment; Uganda
Human immunodeficiency virus-1 (HIV-) associated neurocognitive disorder (HAND) is
characterized by disabling cognitive, behavioral, and motor dysfunction, and is a common
neurological manifestation of advanced HIV infection. HAND in HIV+ individuals in
Uganda is characterized by a relative decline in tests of verbal learning and memory, speed
of information processing, executive function and attention compared to HIV seronegative
controls [Robertson et al. 2007]. The prevalence of HIV- associated dementia (HIV
dementia), the most severe form of HAND, in sub-Saharan Africa is largely unknown, but
one study suggests that the prevalence in Uganda may be 31% among HIV+ individuals
with advanced infection [Wong et al. 2007]. Previous studies of longitudinal
neuropsychological test performance among HIV+ individuals in Uganda have included a
follow-up period of only 6 months. This prior study among HIV+ individuals initiating
stavudine-based combination active antiretroviral therapy (ART) demonstrated improvement
in verbal memory, motor and psychomotor speed, executive functioning, and verbal fluency
performance [Sacktor N et al. 2009]. No previous studies have evaluated neuropsychological
test performance over a longer period.
The objective of this study was to evaluate longitudinal neuropsychological test performance
over a twelve month period among HIV+ individuals, and to evaluate the impact of ART
initiation and baseline neurocognitive status on neuropsychological test changes. Our
hypotheses were that neuropsychological test performance among HIV+ individuals
initiating ART would improve compared to baseline, and would show greater improvement
compared to longitudinal neuropsychological test performance among HIV+ individuals
who did not initiate ART.
METHODS
Participants
The study evaluated 104 HIV+ individuals followed over a 6 month period and 77 HIV+
individuals followed over a 12 month period from an Infectious Disease clinic in Kampala,
Uganda, from August 2009 to October, 2010. The study procedures were approved by the
Johns Hopkins University and Makerere University Institutional Review Boards and ethical
standards committees. Written informed consent was obtained from all patients.
Consecutive ambulatory HIV+ individuals presenting to the Infectious Disease Clinic at the
Infectious Disease Institute in Kampala, Uganda were contacted for participation in the
longitudinal study. Inclusion criteria included HIV infection as documented by ELISA and
confirmed by Western blot or a detectable plasma HIV RNA level. Exclusion criteria
included age <18 years, an active or known past opportunistic infection of the CNS, fever
(temperature >37.5 °C), a history of a chronic neurologic disorder, active psychiatric
disorder, alcoholism, (defined as >30 standard drinks/week), physical deficit (e.g.,
amputation), or severe medical illness that would interfere with the ability to perform the
study evaluations. The evaluations were translated into the local language, Luganda. There
was no targeted recruitment conducted during the enrollment process.
Clinical assessments
HIV+ individuals received clinical assessments using standardized questionnaires of
demographic information and medical, psychiatric, and neurologic history, and underwent a
neurologic examination [Wong et al. 2004; Wong et al. 2007] including assessments of
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cranial nerves, limb strength and coordination, limb vibration and pin sensation, gait, and
deep tendon reflexes in all extremities [Wong et al. 2007]. Patients were also evaluated for
fever, headache, neck stiffness, and focal abnormalities. HIV+ patients with a suspected
opportunistic infection of the central nervous system or neoplasm were excluded from the
study.
The neurocognitive assessment included a screening test for HIV dementia, the International
HIV Dementia Scale (IHDS) [Sacktor et al. 2005] and a full neuropsychological test battery.
The neuropsychological tests for this battery were chosen to be culturally independent and
predominantly non-language based tests that were appropriate for a sub-Saharan African
population and also sensitive for detecting HAND [Wong et al. 2007]. The battery included
predominantly motor and psychomotor speed/executive function tests, although a verbal
memory tests and a simple verbal fluency test were also included. The neuropsychological
testing battery included the World Health Organization–University of California–Los
Angeles Auditory Verbal learning test (AVLT) for verbal memory [Maj et al. 1994]. The
words used in the WHO-UCLA test have been chosen to be universally recognized objects
independent of culture and language. The Timed Gait and Finger Tapping tests were used to
assess motor performance, the Grooved Pegboard test was used to assess psychomotor speed
performance, and the Symbol Digit modalities test [Smith 1982] and Color Trails Test [Maj
et al. 1994] were used to assess executive function. The Digit Span Forward and Backward
was used to assess attention, and the Category Naming test was used to assess verbal
fluency. Functional assessment included the Karnofsky performance scale and the
Instrumental Activities of Daily Living scale of Lawton and Brody [Karnofsky et al. 1948;
Lawton and Brody 1969]. These assessments were used to assign a HAND stage of normal
neurocognitive function, asymptomatic neurocognitive impairment (ANI), mild
neurocognitive disorder (MND), or HIV dementia [Antinori et al. 2007]. A diagnosis of HIV
dementia required impairment in ≥ 3 unrelated neurocognitive domains in which the subject
scored >2.0 standard deviations below the locally determined mean for his or her normative
age and education group. Depression symptoms were assessed with the Center for
Epidemiologic Depression Scale (CES-D) [Beck et al. 1961]. CD4 lymphocyte counts and
plasma HIV viral loads were determined for all HIV+ subjects on the same day as the
neurocognitive assessment.
Data analysis—For each neuropsychological test, a Z score was calculated using age- and
education-adjusted normative data obtained from 100 HIV- uninfected individuals in
Uganda, [Robertson et al. 2007]. Distributional tests have confirmed that the resultant Z
scores follow a normal distribution, and scores are summarized as mean ± (SD). Preliminary
analyses showed that rate of change in cognition did not vary as a function of ART initiation
or baseline neurocognitive status. Therefore, paired samples t-tests were used to evaluate
longitudinal changes (baseline vs. twelve months) in neuropsychological test performance
for the entire sample, as well as for groups defined by ART initiation and baseline
neurocognitive status. Longitudinal changes in neuropsychological test performance
adjusting for CD4 count and antiretroviral therapy initiation were assessed using a general
linear model. An alpha of p< 0.05 was considered significant.
RESULTS
Frequency of HAND and demographic characteristics
At baseline, the HAND stage stratification for the 77 HIV+ individuals followed for twelve
months was as follows: normal neurocognitive function: 11.7%, asymptomatic
neurocognitive impairment (ANI): 15.6%, mild neurocognitive disorder (MND): 33.7%,
HIV dementia: 39.0%. Thirty- one HIV+ individuals (“ART group”) began ART during the
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12 month follow-up period (39% during the first six months), and 46 HIV+ individuals (“no-
ART group”) never received ART during the 12 month follow-up period. The demographic
characteristics of all 77 HIV+ individuals and for ART and no-ART groups are summarized
in Table 1. Individuals in the ART group had a significantly lower mean CD4 count than no-
ART individuals (p<.001). There were no differences between the ART and no-ART groups
on age, education, gender, or plasma HIV RNA level.
Immunological and Virological response to ART
During the 12 month follow-up period, 18 HIV+ individuals initiated the ART combination
of zidovudine, lamivudine, and nevirapine, 10 HIV+ individuals initiated the ART
combination of zidovudine, lamivudine, and efavirenz, and 1 HIV+ individual initiated the
combination of lamivudine and lopinavir. HIV+ individuals initiating ART during the 12
month follow-up period had a significant improvement in CD4 count [mean (SD), (cells/
μL), baseline= 166 (89), 6 month follow-up =221 (113), 12 month follow-up =319 (165)]
(see Table 2) compared to HIV+ individuals not on ART [CD4 count [mean (SD) (cells/
μL)], baseline = 282 (100), 6 month follow-up period = 297 (106), 12 month follow-up
period =251 (105)]. HIV+ individuals initiating ART during the 12 month follow-up period
also had a significant improvement in the plasma HIV RNA level [mean (SD), (copies/ μL)
baseline plasma HIV RNA level =159, 666 (190,455), 12 month follow-up period plasma
HIV RNA level = 14,859 (56,833)] compared to HIV+ individuals not on ART, [mean (SD)
baseline plasma HIV RNA level = 178,922 (239,037), mean (SD) 12 month follow-up
period plasma HIV RNA level = 185,885 (227,224). (A 6 month follow-up plasma HIV
RNA level was not performed). Eighty-eight percent of the HIV+ individuals initiating ART
achieved plasma virologic suppression by 12 months.
Longitudinal neuropsychological test performance for the entire group and stratified by
ART initiation
The performance for each neuropsychological test for the entire group and stratified by ART
status is summarized in Table 3. The entire group showed improvement in tests of verbal
memory (AVLT total, short delay, long delay, and recognition), executive functioning
(Color Trails 1 and 2, Symbol Digit), motor (Timed Gait, Finger Tapping), and psychomotor
speed (Grooved Pegboard) performance. Both the ART and no-ART groups showed
improvement in tests of verbal memory, executive functioning, motor, and psychomotor
speed performance, as well as depression symptoms assessed using the CES-D. The ART
group had improvement in CD4 lymphocyte counts over the 12 months (p <.001) whereas
the no-ART group had no CD4 lymphocyte count improvement. After adjusting for baseline
CD4 cell count and ART initiation in the model, the improvements in tests of verbal
memory, executive functioning, motor, and psychomotor speed performance, as well as
depression symptoms remain significant.
Longitudinal neuropsychological test performance stratified by baseline HAND stage
The longitudinal neuropsychological test performance stratified by baseline HAND stage at
6 and 12 months are described in Tables 5 and 6 respectively.. For the HIV+ individuals
with normal cognition at baseline (n=9), the only neuropsychological tests showing
improvement over 12 months were the verbal fluency test (p=0.01) and a single test of
motor speed [Timed Gait (p=0.04)]. For HIV+ individuals with ANI at baseline (n=12), the
only tests showing improvement over 12 months were two tests of verbal memory [AVLT
total (p=0.001), AVLT long delay (p=0.02)], a test of executive functioning [Symbol Digit
(p-0.05)], and a test of motor speed [Timed Gait, p=0.001]. For HIV+ individuals with
MND at baseline (n=26), many tests showed improvement including three tests of verbal
memory [AVLT total, (p=0.05), AVLT short delay (p=0.01), AVLT long delay (p=0.02)],
two tests of executive functioning [Color Trails 1 (p=0.008), and Color Trails 2 (p=0.005)],
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two tests of motor speed [Timed Gait (p=0.01), and Finger Tapping (p=0.005)], and one test
of psychomotor speed [Grooved Pegboard nondominant (p=0.004)]. For HIV+ individuals
with dementia at baseline n=30), again many tests showed improvement including all four
tests of verbal memory [AVLT total (p=0.008), AVLT short delay (p=0.02), AVLT long
delay (p=0.004), and AVLT recognition (p=0.01)], three tests of executive functioning
[Color Trails 1 (p=0.04), Color Trails 2 (<0.001), and Symbol Digit (p=0.03)], and two tests
of psychomotor speed [(Grooved Pegboard dominant (p <0.001) and Grooved Pegboard
nondominant (p< 0.001)].
DISCUSSION
Neuropsychological test performance among HIV+ individuals in sub-Saharan Africa was
first evaluated in Kenya and Zaire in a cross-sectional study conducted by the World Health
Organization in 1994 [Maj et al. 1994]. More recent studies of neuropsychological test
performance among HIV+ adults in Africa using a detailed neuropsychological test battery
have all been cross-sectional studies performed in Ethiopia [Clifford et al. 2007], Nigeria
[Salawu et al. 2008] Botswanna [Lawler et al. 2010], Malawi [Patel et al. 2010], South
Africa [Joska et al. 2011] Cameroon [Kanmogne et al. 2010] Kenya, [Kwasa et al. 2012],
and Zambia [Hestad et al. 2012], [Birbeck et al. 2011]. A prior longitudinal study of
neuropsychological test performance in sub-Saharan Africa was conducted in Uganda
[Sacktor et al. 2009] over a six month period. In this study, HIV+ individuals with cognitive
impairment at baseline demonstrated significant improvement on a test of executive function
(the Color Trails 2 test) compared to HIV seronegative individuals also evaluated for a 6
month period. Another study, the AIDS Clinical Trials Group 5199 study, used an
abbreviated neuropsychological test battery including tests of motor performance and verbal
fluency every 6 months for a median of 16 weeks at multiple international sites, including
locations in Malawi, South Africa, and Zimbabwe [Robertson et al. 2012]. There are no
prior studies using a detailed neuropsychological test performance among HIV+ individuals
over a 12 month period in sub-Saharan Africa.
Our results suggest that HAND continues to be a significant neurological condition among
HIV+ individuals in Uganda. Thirty-nine percent of the HIV+ individuals entering our study
were diagnosed with dementia at baseline which is slightly higher than the 31% of HIV+
individuals with dementia in a previous study performed by our group [Wong et al. 2007].
Both studies had HIV+ individuals with a mean CD4 lymphocyte count at baseline in the
low 200’s.
Our results also suggest that when HIV+ individuals in Uganda enter a clinical research
study, they have significant improvement in their neuropsychological test performance over
a 12 month period. This improvement in neuropsychological test performance at 12 months
in HIV+ individuals initiating ART is similar to the improvement seen at 6 months in HIV+
individuals initiating ART in a prior study in Uganda [Sacktor N et al. 2009]. This
improvement was seen predominantly in HIV+ individuals who had MND and dementia at
baseline. Surprisingly, in contrast to our hypothesis, we did not see greater improvement in
HIV+ individuals who initiated ART during the 12 month period compared to the HIV+
individuals who never started ART.
Several potential explanations could account for this finding. Practice effects from
administration of the neuropsychological tests on multiple occasions could account for some
of the improvement. Our study did not include an HIV seronegative (HIV-) control group
for comparison to evaluate for practice effects. However, the improvement in
neuropsychological test performance at six months among HIV+ individuals not on ART,
exceeds the improvements due to practice effects at 6 months from HIV− individuals in a
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previous study conducted by our group in Uganda (data not shown). Future longitudinal
studies of neuropsychological test performance should include a demographically matched
HIV- control group if feasible.
Although a subgroup of HIV+ individuals did not initiate ART, they were enrolled in a
clinical research study at the Infectious Disease Institute in Kampala, Uganda, and received
the medical and psychosocial support services available through the Institute. These services
likely improved the overall quality of life for these HIV+ individuals, which could account
for the neuropsychological test improvement seen with these individuals. Indeed, the HIV+
individuals who were not on ART did have significant improvement in their depression
symptomatology on the CES-D, reflecting an overall improvement in their quality of life.
This finding is an important consideration in future longitudinal studies of
neuropsychological test performance in a resource limited country.
There are several limitations to this study which should be noted. We did not include an
HIV- control group to evaluate for practice effects. Our assessments for functional status
may not be ideal for examining functional status in a resource limited country such as
Uganda. This limitation impacts the relative proportion of individuals assigned to each stage
of HAND. Informant interviews for functional status were not available for the individuals
in this study.
Our results are the first examination of longitudinal neuropsychological test performance
over a twelve month period in well-characterized HIV+ individuals who started ART and
those who did not in sub-Saharan Africa. Our results indicate that improvements in
longitudinal neuropsychological test performance over twelve months can occur in both HIV
+ individuals who initiate ART and HIV+ individuals who do not initiate ART. Thus
improvements in neuropsychological test performance in HIV+ individuals initiating ART
in sub-Saharan Africa need to be interpreted with caution. Some of the neurocognitive
improvement may be due to the effect of ART in suppressing virological replication and
improving immunological function. However, some of the neurocognitive improvement may
also be due to the impact of receiving medical and psychosocial support services, reduction
in depression symptomatology, and improvements in overall quality of life. Practice effects
could also account for some of the improvement. These factors need to be considered in
future studies evaluating longitudinal neuropsychological test performance in HIV+
individuals initiating ART in resource limited countries. Future studies should also include a
larger number of individuals followed over a long period of follow-up with the inclusion of
demographically matched HIV- controls.
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Table 1
Demographic characteristics of HIV infected individuals, total and stratified by initiation of combination
antiretroviral therapy (ART) during the 12 month follow-up period
Characteristic Total On ART No ART
Age, years [Mean (SD)] 37.3 (7.4) 38.0 (8.3) 36.2 (6.5)
Education, years [Mean (SD)] 8.3 (3.8) 8.4 (4.2) 8.1 (3.6)
Gender, % male 38 36 39
CD4 lymphocyte count, cells/μL [Mean (SD)] 235 (111) 166 (89) 282 (100)
Plasma HIV RNA level, copies/mL [Mean (SD)] 171,170 (219,638) 159,666 (190,455) 178,922 (239,037)
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Table 2
Longitudinal CD4 lymphocyte count and plasma HIV RNA changes among HIV+ individuals stratified by
ART initiation
On ART (n=31) No ART (n=46)
CD4 count (cells/μL), Mean (SD)
Baseline 166 (89) 282 (100)
6 month follow-up 221 (113) 297 (106)
12 month follow-up 319 (165) 251 (105)
Plasma HIV RNA level copies/μL, mean (SD) *
Baseline 159,666 (190,455) 178,922 (239,037)
12 month follow-up 14,859 (56,833) 185,885 (227,224)
*
6 month follow-up plasma HIV RNA level was not performed.
ART=antiretroviral therapy
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